1. Scrip
  2. >>Focus On Asia
  3. >>China

Pharmula Acquisition To Provide US Expansion Base For Jingxin

 
• By Ying Huang

Shanghai-listed Jingxin Pharmaceutical is aiming to tap into the US market for its growing formulations business through the majority acquisition of Pharmula, a US-based contract services firm. The Chinese manufacturer is looking to capitalize on its partners’ strength in R&D to facilitate its global expansion.

SHANGHAI - Zhejiang Jingxin Pharmaceutical Co. Ltd. has acquired a 51% stake in the US contract research organization (CRO) Pharmula Laboratories for $1.02m in cash, marking the first step by the Shanghai-listed manufacturing company to tap into an overseas market for its formulation business.

The purchase of the majority stake in Pharmula indicates the company’s international R&D deployment, Jingxin said in a statement, in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Chinese Biotechs Raise New Funds On Potential First-In-Class Assets

 
• By Dexter Jie Yan

Helped by their development of novel potential first-in-class therapies, Tcelltech, BioTroy and Xiaolu are among the Chinese ventures to have attracted new funding from investors over the past weeks.

GSK Gains Hengrui’s PDE3/4 Inhibitor, Options For 11 Early Assets In Potential $12bn Deal

 
• By Dexter Jie Yan

Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.

Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II

 
• By Dexter Jie Yan

Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

More from Focus On Asia

GSK Gains Hengrui’s PDE3/4 Inhibitor, Options For 11 Early Assets In Potential $12bn Deal

 
• By Dexter Jie Yan

Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.

Korean Biopharma Catching Up On AI, But What Are The Challenges?

 
• By Jung Won Shin

While South Korea's biopharma sector has made progress in its digital transformation, including the adoption of AI technologies, a recent report has identified multiple remaining challenges.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

 
• By Anju Ghangurde

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.